Beyond market averages, investors seeking exceptional growth focus on the art of stock selection. The right picks can significantly contribute to the expansion of your wealth.
The closing price of Alnylam Pharmaceuticals Inc (NASDAQ: ALNY) was $415.21 for the day, down -3.44% from the previous closing price of $430.02. In other words, the price has decreased by -$3.44 from its previous closing price. On the day, 1.61 million shares were traded. ALNY stock price reached its highest trading level at $433.305 during the session, while it also had its lowest trading level at $414.45.
Ratios:
Our analysis of ALNY’s different ratios will help us gain a deeper understanding of the company. It provided that stocks Price–to–Cash (P/C) ratio for the trailing twelve months (TTM) is standing at 20.13 whereas its Price-to-Free Cash Flow (P/FCF) for the term is 247.81. For the most recent quarter (mrq), Quick Ratio is recorded 2.49 and its Current Ratio is at 2.54. In the meantime, Its Debt-to-Equity ratio is 11.86 whereas as Long-Term Debt/Eq ratio is at 11.17.
On August 04, 2025, Oppenheimer Upgraded its rating to Outperform which previously was Perform but kept the price unchanged to $490.
Insider Transactions:
Also, insider trades can serve as a great indicator of what management thinks about the future direction of a stock’s price. A recent insider transaction in this stock occurred on Nov 17 ’25 when Fitzgerald Kevin Joseph sold 12,128 shares for $452.18 per share. The transaction valued at 5,483,990 led to the insider holds 21,264 shares of the business.
Fitzgerald Kevin Joseph bought 12,128 shares of ALNY for $5,445,472 on Nov 17 ’25. On Nov 12 ’25, another insider, Greenstreet Yvonne, who serves as the Chief Executive Officer of the company, sold 15,650 shares for $453.69 each. As a result, the insider received 7,100,322 and left with 65,409 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, ALNY now has a Market Capitalization of 54854975488 and an Enterprise Value of 56860270592. As of this moment, Alnylam’s Price-to-Earnings (P/E) ratio for their current fiscal year is 1727.16, and their Forward P/E ratio for the next fiscal year is 55.16. For the stock, the TTM Price-to-Sale (P/S) ratio is 17.09 while its Price-to-Book (P/B) ratio in mrq is 233.96. Its current Enterprise Value per Revenue stands at 17.713 whereas that against EBITDA is 177.123.
Stock Price History:
The Beta on a monthly basis for ALNY is 0.31, which has changed by 0.6919929 over the last 52 weeks, in comparison to a change of 0.12529528 over the same period for the S&P500. Over the past 52 weeks, ALNY has reached a high of $495.55, while it has fallen to a 52-week low of $205.87. The 50-Day Moving Average of the stock is -8.92%, while the 200-Day Moving Average is calculated to be 15.51%.
Shares Statistics:
ALNY traded an average of 1.12M shares per day over the past three months and 1162220 shares per day over the past ten days. A total of 131.79M shares are outstanding, with a floating share count of 129.77M. Insiders hold about 1.77% of the company’s shares, while institutions hold 99.36% stake in the company. Shares short for ALNY as of 1763078400 were 4279250 with a Short Ratio of 3.83, compared to 1760486400 on 3993922. Therefore, it implies a Short% of Shares Outstanding of 4279250 and a Short% of Float of 4.2600001999999995.
Earnings Estimates
. The current assessment of Alnylam Pharmaceuticals Inc (ALNY) involves the perspectives of 11.0 analysts closely monitoring its market dynamics.The consensus estimate for the next quarter is $2.09, with high estimates of $2.55 and low estimates of $1.55.
Analysts are recommending an EPS of between $5.99 and $3.76 for the fiscal current year, implying an average EPS of $4.96. EPS for the following year is $10.61, with 12.0 analysts recommending between $13.86 and $6.44.
Revenue Estimates
It is expected that $90B in revenue will be generated in. The current quarter, according to 20 analysts. It ranges from a high estimate of $1.61B to a low estimate of $1.04B. As of. The current estimate, Alnylam Pharmaceuticals Inc’s year-ago sales were $593.17MFor the next quarter, 20 analysts are estimating revenue of $1.22B. There is a high estimate of $1.31B for the next quarter, whereas the lowest estimate is $1.11B.
A total of 25 analysts have provided revenue estimates for ALNY’s current fiscal year. The highest revenue estimate was $4.23B, while the lowest revenue estimate was $3.42B, resulting in an average revenue estimate of $3.74B. In the same quarter a year ago, actual revenue was $2.25BBased on 24 analysts’ estimates, the company’s revenue will be $5.35B in the next fiscal year. The high estimate is $6.12B and the low estimate is $4.34B.
